Prelude Therapeutics Inc [NASDAQ: PRLD] jumped around 0.08 points on Wednesday, while shares priced at $1.67 at the close of the session, up 5.03%.
Prelude Therapeutics Inc stock is now 76.03% up from its year-to-date (YTD) trading value. PRLD Stock saw the intraday high of $1.68 and lowest of $1.54 per share. The company’s 52-week high price is 4.22, which means current price is +173.73% above from all time high which was touched on 11/03/25.
Compared to the average trading volume of 1.32M shares, PRLD reached a trading volume of 296665 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Prelude Therapeutics Inc [PRLD]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PRLD shares is $4.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PRLD stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Prelude Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 19, 2024. The new note on the price target was released on June 20, 2024, representing the official price target for Prelude Therapeutics Inc stock. Previously, the target price had yet another raise to $7, while JMP Securities analysts kept a Mkt Outperform rating on PRLD stock.
The Price to Book ratio for the last quarter was 1.61, with the Price to Cash per share for the same quarter was set at 0.73.
How has PRLD stock performed recently?
Prelude Therapeutics Inc [PRLD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by 0.00. With this latest performance, PRLD shares gained by 8.44% in over the last four-week period, additionally plugging by 85.16% over the last 6 months – not to mention a rise of 30.98% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PRLD stock in for the last two-week period is set at 52.18, with the RSI for the last a single of trading hit 0.2645, and the three-weeks RSI is set at 0.2819 for Prelude Therapeutics Inc [PRLD]. The present Moving Average for the last 50 days of trading for this stock 1.4775, while it was recorded at 1.5860 for the last single week of trading, and 1.0322 for the last 200 days.
Prelude Therapeutics Inc [PRLD]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Prelude Therapeutics Inc [PRLD] shares currently have an operating margin of -1152.85% and a Gross Margin at 83.03%. Prelude Therapeutics Inc’s Net Margin is presently recorded at -1064.50%.
Prelude Therapeutics Inc (PRLD) Capital Structure & Debt Analysis
According to recent financial data for Prelude Therapeutics Inc. ( PRLD), the Return on Equity (ROE) stands at -103.99%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -76.56%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Prelude Therapeutics Inc’s Return on Invested Capital (ROIC) is -151.74%, showcasing its effectiveness in deploying capital for earnings.
Prelude Therapeutics Inc (PRLD) Efficiency & Liquidity Metrics
Based on Prelude Therapeutics Inc’s (PRLD) latest financial statements, the Debt-to-Equity Ratio is 0.30%, indicating its reliance on debt financing relative to shareholder equity.
Prelude Therapeutics Inc (PRLD) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Prelude Therapeutics Inc. (PRLD) effectively leverages its workforce, generating an average of -$853206.11 per employee. The company’s liquidity position is robust, with a Current Ratio of 3.21% and a Quick Ratio of 3.21%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Prelude Therapeutics Inc [PRLD]
With the latest financial reports released by the company, Prelude Therapeutics Inc posted -0.37/share EPS, while the average EPS was predicted by analysts to be reported at -0.47/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.1. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PRLD.
Insider trade positions for Prelude Therapeutics Inc [PRLD]
There are presently around $54.45%, or 60.46%% of PRLD stock, in the hands of institutional investors. The top three institutional holders of PRLD stocks are: ORBIMED ADVISORS LLC with ownership of 10.91 million shares, which is approximately 14.4043%. BAKER BROS. ADVISORS LP, holding 10.12 million shares of the stock with an approximate value of $$38.57 million in PRLD stocks shares; and BAKER BROS. ADVISORS LP, currently with $$15.75 million in PRLD stock with ownership which is approximately 5.4571%.
